



ASX Announcement

23 October 2012

NEWLY-PUBLISHED STUDY ON SIR-SPHERES® MICROSPHERES SHOWS DOUBLING OF OVERALL SURVIVAL

Sydney, NSW, Australia, 23 October 2012 – Sirtex Medical Limited (SRX-ASX) today reported that a newly-published study by investigators from the University of Magdeburg, Germany, showed that patients with metastatic colorectal cancer experienced a statistically-significant survival benefit from treatment with SIR-Spheres® microspheres, compared to patients who received the best available supportive care for their disease.

“These patients were treated in the salvage setting, when they had exhausted all other treatment options. This was the first comparative study of SIR-Spheres microspheres, in this group of patients in which survival was the primary endpoint,” said Gilman Wong, Chief Executive Officer of Sirtex Medical Limited. “We are particularly pleased that the authors chose to point out in this article that the benefit they observed with SIR-Spheres compared favourably with that seen in clinical trials with biologic agents such as cetuximab and panitumumab.

The study, by Dr. Ricarda Seidensticker and her colleagues, entitled “Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases,” appears in the current issue of the international journal, *Cardiovascular and Interventional Radiology*, 2012; 35 (5): 1066-1073. The authors observed in this study in 58 patients that median overall survival of SIR-Spheres microspheres treated patients was 8.3 months compared to only 3.5 months for the patients who received best supportive care, a finding that is highly statistically significant ($P < 0.001$).

“These positive findings add to the rapidly growing evidence demonstrating the effectiveness of SIR-Spheres microspheres in the treatment of patients with liver metastases from primary colorectal cancer,” Mr. Wong stated. “We look forward to the results becoming available from Sirtex’s ongoing SIRFLOX and FOXFIRE randomised controlled trials. These two studies aim to determine the exact role that SIR-Spheres microspheres may play when utilised earlier in the treatment cascade, in combination with first-line chemotherapy in this large patient population...”

For further information please contact:

Gilman Wong

CEO Sirtex Medical Limited

(02) 9964 8400

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.